Tag Archives: organic
Plants are the planet’s lungs, but they’re struggling to keep up due to rising CO2 emissions and deforestation. Engineers are giving them a helping hand, though, by augmenting their capacity with new technology and creating artificial substitutes to help them clean up our atmosphere.
Imperial College London, one of the UK’s top engineering schools, recently announced that it was teaming up with startup Arborea to build the company’s first outdoor pilot of its BioSolar Leaf cultivation system at the university’s White City campus in West London.
Arborea is developing large solar panel-like structures that house microscopic plants and can be installed on buildings or open land. The plants absorb light and carbon dioxide as they photosynthesize, removing greenhouse gases from the air and producing organic material, which can be processed to extract valuable food additives like omega-3 fatty acids.
The idea of growing algae to produce useful materials isn’t new, but Arborea’s pitch seems to be flexibility and affordability. The more conventional approach is to grow algae in open ponds, which are less efficient and open to contamination, or in photo-bioreactors, which typically require CO2 to be piped in rather than getting it from the air and can be expensive to run.
There’s little detail on how the technology deals with issues like nutrient supply and harvesting or how efficient it is. The company claims it can remove carbon dioxide as fast as 100 trees using the surface area of just a single tree, but there’s no published research to back that up, and it’s hard to compare the surface area of flat panels to that of a complex object like a tree. If you flattened out every inch of a tree’s surface it would cover a surprisingly large area.
Nonetheless, the ability to install these panels directly on buildings could present a promising way to soak up the huge amount of CO2 produced in our cities by transport and industry. And Arborea isn’t the only one trying to give plants a helping hand.
For decades researchers have been working on ways to use light-activated catalysts to split water into oxygen and hydrogen fuel, and more recently there have been efforts to fuse this with additional processes to combine the hydrogen with carbon from CO2 to produce all kinds of useful products.
Most notably, in 2016 Harvard researchers showed that water-splitting catalysts could be augmented with bacteria that combines the resulting hydrogen with CO2 to create oxygen and biomass, fuel, or other useful products. The approach was more efficient than plants at turning CO2 to fuel and was built using cheap materials, but turning it into a commercially viable technology will take time.
Not everyone is looking to mimic or borrow from biology in their efforts to suck CO2 out of the atmosphere. There’s been a recent glut of investment in startups working on direct-air capture (DAC) technology, which had previously been written off for using too much power and space to be practical. The looming climate change crisis appears to be rewriting some of those assumptions, though.
Most approaches aim to use the concentrated CO2 to produce synthetic fuels or other useful products, creating a revenue stream that could help improve their commercial viability. But we look increasingly likely to surpass the safe greenhouse gas limits, so attention is instead turning to carbon-negative technologies.
That means capturing CO2 from the air and then putting it into long-term storage. One way could be to grow lots of biomass and then bury it, mimicking the process that created fossil fuels in the first place. Or DAC plants could pump the CO2 they produce into deep underground wells.
But the former would take up unreasonably large amounts of land to make a significant dent in emissions, while the latter would require huge amounts of already scant and expensive renewable power. According to a recent analysis, artificial photosynthesis could sidestep these issues because it’s up to five times more efficient than its natural counterpart and could be cheaper than DAC.
Whether the technology will develop quickly enough for it to be deployed at scale and in time to mitigate the worst effects of climate change remains to be seen. Emissions reductions certainly present a more sure-fire way to deal with the problem, but nonetheless, cyborg plants could soon be a common sight in our cities.
Image Credit: GiroScience / Shutterstock.com Continue reading
A few years back, DeepMind’s Demis Hassabis famously prophesized that AI and neuroscience will positively feed into each other in a “virtuous circle.” If realized, this would fundamentally expand our insight into intelligence, both machine and human.
We’ve already seen some proofs of concept, at least in the brain-to-AI direction. For example, memory replay, a biological mechanism that fortifies our memories during sleep, also boosted AI learning when abstractly appropriated into deep learning models. Reinforcement learning, loosely based on our motivation circuits, is now behind some of AI’s most powerful tools.
Hassabis is about to be proven right again.
Last week, two studies independently tapped into the power of ANNs to solve a 70-year-old neuroscience mystery: how does our visual system perceive reality?
The first, published in Cell, used generative networks to evolve DeepDream-like images that hyper-activate complex visual neurons in monkeys. These machine artworks are pure nightmare fuel to the human eye; but together, they revealed a fundamental “visual hieroglyph” that may form a basic rule for how we piece together visual stimuli to process sight into perception.
In the second study, a team used a deep ANN model—one thought to mimic biological vision—to synthesize new patterns tailored to control certain networks of visual neurons in the monkey brain. When directly shown to monkeys, the team found that the machine-generated artworks could reliably activate predicted populations of neurons. Future improved ANN models could allow even better control, giving neuroscientists a powerful noninvasive tool to study the brain. The work was published in Science.
The individual results, though fascinating, aren’t necessarily the point. Rather, they illustrate how scientists are now striving to complete the virtuous circle: tapping AI to probe natural intelligence. Vision is only the beginning—the tools can potentially be expanded into other sensory domains. And the more we understand about natural brains, the better we can engineer artificial ones.
It’s a “great example of leveraging artificial intelligence to study organic intelligence,” commented Dr. Roman Sandler at Kernel.co on Twitter.
ANNs and biological vision have quite the history.
In the late 1950s, the legendary neuroscientist duo David Hubel and Torsten Wiesel became some of the first to use mathematical equations to understand how neurons in the brain work together.
In a series of experiments—many using cats—the team carefully dissected the structure and function of the visual cortex. Using myriads of images, they revealed that vision is processed in a hierarchy: neurons in “earlier” brain regions, those closer to the eyes, tend to activate when they “see” simple patterns such as lines. As we move deeper into the brain, from the early V1 to a nub located slightly behind our ears, the IT cortex, neurons increasingly respond to more complex or abstract patterns, including faces, animals, and objects. The discovery led some scientists to call certain IT neurons “Jennifer Aniston cells,” which fire in response to pictures of the actress regardless of lighting, angle, or haircut. That is, IT neurons somehow extract visual information into the “gist” of things.
That’s not trivial. The complex neural connections that lead to increasing abstraction of what we see into what we think we see—what we perceive—is a central question in machine vision: how can we teach machines to transform numbers encoding stimuli into dots, lines, and angles that eventually form “perceptions” and “gists”? The answer could transform self-driving cars, facial recognition, and other computer vision applications as they learn to better generalize.
Hubel and Wiesel’s Nobel-prize-winning studies heavily influenced the birth of ANNs and deep learning. Much of earlier ANN “feed-forward” model structures are based on our visual system; even today, the idea of increasing layers of abstraction—for perception or reasoning—guide computer scientists to build AI that can better generalize. The early romance between vision and deep learning is perhaps the bond that kicked off our current AI revolution.
It only seems fair that AI would feed back into vision neuroscience.
Hieroglyphs and Controllers
In the Cell study, a team led by Dr. Margaret Livingstone at Harvard Medical School tapped into generative networks to unravel IT neurons’ complex visual alphabet.
Scientists have long known that neurons in earlier visual regions (V1) tend to fire in response to “grating patches” oriented in certain ways. Using a limited set of these patches like letters, V1 neurons can “express a visual sentence” and represent any image, said Dr. Arash Afraz at the National Institute of Health, who was not involved in the study.
But how IT neurons operate remained a mystery. Here, the team used a combination of genetic algorithms and deep generative networks to “evolve” computer art for every studied neuron. In seven monkeys, the team implanted electrodes into various parts of the visual IT region so that they could monitor the activity of a single neuron.
The team showed each monkey an initial set of 40 images. They then picked the top 10 images that stimulated the highest neural activity, and married them to 30 new images to “evolve” the next generation of images. After 250 generations, the technique, XDREAM, generated a slew of images that mashed up contorted face-like shapes with lines, gratings, and abstract shapes.
This image shows the evolution of an optimum image for stimulating a visual neuron in a monkey. Image Credit: Ponce, Xiao, and Schade et al. – Cell.
“The evolved images look quite counter-intuitive,” explained Afraz. Some clearly show detailed structures that resemble natural images, while others show complex structures that can’t be characterized by our puny human brains.
This figure shows natural images (right) and images evolved by neurons in the inferotemporal cortex of a monkey (left). Image Credit: Ponce, Xiao, and Schade et al. – Cell.
“What started to emerge during each experiment were pictures that were reminiscent of shapes in the world but were not actual objects in the world,” said study author Carlos Ponce. “We were seeing something that was more like the language cells use with each other.”
This image was evolved by a neuron in the inferotemporal cortex of a monkey using AI. Image Credit: Ponce, Xiao, and Schade et al. – Cell.
Although IT neurons don’t seem to use a simple letter alphabet, it does rely on a vast array of characters like hieroglyphs or Chinese characters, “each loaded with more information,” said Afraz.
The adaptive nature of XDREAM turns it into a powerful tool to probe the inner workings of our brains—particularly for revealing discrepancies between biology and models.
The Science study, led by Dr. James DiCarlo at MIT, takes a similar approach. Using ANNs to generate new patterns and images, the team was able to selectively predict and independently control neuron populations in a high-level visual region called V4.
“So far, what has been done with these models is predicting what the neural responses would be to other stimuli that they have not seen before,” said study author Dr. Pouya Bashivan. “The main difference here is that we are going one step further and using the models to drive the neurons into desired states.”
It suggests that our current ANN models for visual computation “implicitly capture a great deal of visual knowledge” which we can’t really describe, but which the brain uses to turn vision information into perception, the authors said. By testing AI-generated images on biological vision, however, the team concluded that today’s ANNs have a degree of understanding and generalization. The results could potentially help engineer even more accurate ANN models of biological vision, which in turn could feed back into machine vision.
“One thing is clear already: Improved ANN models … have led to control of a high-level neural population that was previously out of reach,” the authors said. “The results presented here have likely only scratched the surface of what is possible with such implemented characterizations of the brain’s neural networks.”
To Afraz, the power of AI here is to find cracks in human perception—both our computational models of sensory processes, as well as our evolved biological software itself. AI can be used “as a perfect adversarial tool to discover design cracks” of IT, said Afraz, such as finding computer art that “fools” a neuron into thinking the object is something else.
“As artificial intelligence researchers develop models that work as well as the brain does—or even better—we will still need to understand which networks are more likely to behave safely and further human goals,” said Ponce. “More efficient AI can be grounded by knowledge of how the brain works.”
Image Credit: Sangoiri / Shutterstock.com Continue reading
Shopping is becoming less and less of a consumer experience—or, for many, less of a chore—as the list of things that can be bought online and delivered to our homes grows to include, well, almost anything you can think of. An Israeli startup is working to make shopping and deliveries even faster and cheaper—and they’re succeeding.
Last week, CommonSense Robotics announced the launch of its first autonomous micro-fulfillment center in Tel Aviv. The company claims the facility is the smallest of its type in the world at 6,000 square feet. For comparison’s sake—most fulfillment hubs that incorporate robotics are at least 120,000 square feet. Amazon’s upcoming facility in Bessemer, Alabama will be a massive 855,000 square feet.
The thing about a building whose square footage is in the hundred-thousands is, you can fit a lot of stuff inside it, but there aren’t many places you can fit the building itself, especially not in major urban areas. So most fulfillment centers are outside cities, which means more time and more money to get your Moroccan oil shampoo, or your vegetable garden starter kit, or your 100-pack of organic protein bars from that fulfillment center to your front door.
CommonSense Robotics built the Tel Aviv center in an area that was previously thought too small for warehouse infrastructure. “In order to fit our site into small, tight urban spaces, we’ve designed every single element of it to optimize for space efficiency,” said Avital Sterngold, VP of operations. Using a robotic sorting system that includes hundreds of robots, plus AI software that assigns them specific tasks, the facility can prepare orders in less than five minutes end-to-end.
It’s not all automated, though—there’s still some human labor in the mix. The robots fetch goods and bring them to a team of people, who then pack the individual orders.
CommonSense raised $20 million this year in a funding round led by Palo Alto-based Playground Global. The company hopes to expand its operations to the US and UK in 2019. Its business model is to charge retailers a fee for each order fulfilled, while maintaining ownership and operation of the fulfillment centers. The first retailers to jump on the bandwagon were Super-Pharm, a drugstore chain, and Rami Levy, a retail supermarket chain.
“Staying competitive in today’s market is anchored by delivering orders quickly and determining how to fulfill and deliver orders efficiently, which are always the most complex aspects of any ecommerce operation. With robotics, we will be able to fulfill and deliver orders in under one hour, all while saving costs on said fulfillment and delivery,” said Super-Pharm VP Yossi Cohen. “Before CommonSense Robotics, we offered our customers next-day home delivery. With this partnership, we are now able to offer our customers same-day delivery and will very soon be offering them one-hour delivery.”
Long live the instant gratification economy—and the increasingly sophisticated technology that’s enabling it.
Image Credit: SasinTipchai / Shutterstock.com Continue reading
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading
The new Blade Runner sequel will return us to a world where sophisticated androids made with organic body parts can match the strength and emotions of their human creators. As someone who builds biologically inspired robots, I’m interested in whether our own technology will ever come close to matching the “replicants” of Blade Runner 2049.
The reality is that we’re a very long way from building robots with human-like abilities. But advances in so-called soft robotics show a promising way forward for technology that could be a new basis for the androids of the future.
From a scientific point of view, the real challenge is replicating the complexity of the human body. Each one of us is made up of millions and millions of cells, and we have no clue how we can build such a complex machine that is indistinguishable from us humans. The most complex machines today, for example the world’s largest airliner, the Airbus A380, are composed of millions of parts. But in order to match the complexity level of humans, we would need to scale this complexity up about a million times.
There are currently three different ways that engineering is making the border between humans and robots more ambiguous. Unfortunately, these approaches are only starting points and are not yet even close to the world of Blade Runner.
There are human-like robots built from scratch by assembling artificial sensors, motors, and computers to resemble the human body and motion. However, extending the current human-like robot would not bring Blade Runner-style androids closer to humans, because every artificial component, such as sensors and motors, are still hopelessly primitive compared to their biological counterparts.
There is also cyborg technology, where the human body is enhanced with machines such as robotic limbs and wearable and implantable devices. This technology is similarly very far away from matching our own body parts.
Finally, there is the technology of genetic manipulation, where an organism’s genetic code is altered to modify that organism’s body. Although we have been able to identify and manipulate individual genes, we still have a limited understanding of how an entire human emerges from genetic code. As such, we don’t know the degree to which we can actually program code to design everything we wish.
Soft robotics: a way forward?
But we might be able to move robotics closer to the world of Blade Runner by pursuing other technologies and, in particular, by turning to nature for inspiration. The field of soft robotics is a good example. In the last decade or so, robotics researchers have been making considerable efforts to make robots soft, deformable, squishable, and flexible.
This technology is inspired by the fact that 90% of the human body is made from soft substances such as skin, hair, and tissues. This is because most of the fundamental functions in our body rely on soft parts that can change shape, from the heart and lungs pumping fluid around our body to the eye lenses generating signals from their movement. Cells even change shape to trigger division, self-healing and, ultimately, the evolution of the body.
The softness of our bodies is the origin of all their functionality needed to stay alive. So being able to build soft machines would at least bring us a step closer to the robotic world of Blade Runner. Some of the recent technological advances include artificial hearts made out of soft functional materials that are pumping fluid through deformation. Similarly, soft, wearable gloves can help make hand grasping stronger. And “epidermal electronics” has enabled us to tattoo electronic circuits onto our biological skins.
Softness is the keyword that brings humans and technologies closer together. Sensors, motors, and computers are all of a sudden integrated into human bodies once they became soft, and the border between us and external devices becomes ambiguous, just like soft contact lenses became part of our eyes.
Nevertheless, the hardest challenge is how to make individual parts of a soft robot body physically adaptable by self-healing, growing, and differentiating. After all, every part of a living organism is also alive in biological systems in order to make our bodies totally adaptable and evolvable, the function of which could make machines totally indistinguishable from ourselves.
It is impossible to predict when the robotic world of Blade Runner might arrive, and if it does, it will probably be very far in the future. But as long as the desire to build machines indistinguishable from humans is there, the current trends of robotic revolution could make it possible to achieve that dream.
This article was originally published on The Conversation. Read the original article.
Image Credit: Dariush M / Shutterstock.com Continue reading